secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179837
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate
--------------------------------------------------------------------------------

- Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
- Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.
- Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.
- Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.
- Recent public offering generated $230M gross proceeds, strengthening balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/0001193125-25-179837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/elvn-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer